Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 150

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS)

Moayyedi, Paul, Andrews, Christopher N, MacQueen, Glenda, Korownyk, Christina, Marsiglio, Megan, Graff, Lesley, Kvern, Brent, Lazarescu, Adriana, Liu, Louis, Paterson, William G, Sidani, Sacha, Vanner, Stephen·2019·Journal of the Canadian Association of Gastroenterology
DOI 10.1093/jcag/gwy071
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jcag/gwy071

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Research works printed but not linked: 141

  1. Lacy, 2016, Bowel disorders, Gastroenterology, 150, 1393, 10.1053/j.gastro.2016.02.031 · DOI · Paper page
  2. Thompson, 2002, Functional gastrointestinal disorders in Canada: First population-based survey using Rome II criteria with suggestions for improving the questionnaire, Dig Dis Sci, 47, 225, 10.1023/A:1013208713670 · DOI · Paper page
  3. Palsson, 2016, Population prevalence of Rome IV and Rome III irritable bowel syndrome (IBS) in the United States (US), Canada and the United Kingdom (UK) [Abstract Mo1642], Gastroenterology, 150, 10.1016/S0016-5085(16)32513-6 · DOI
  4. Drossman, 2016, Functional gastrointestinal disorders: History, pathophysiology, clinical features and Rome IV, Gastroenterology, 150, 1262, 10.1053/j.gastro.2016.02.032 · DOI
  5. Ford, 2014, American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation, Am J Gastroenterol, 109, S2, 10.1038/ajg.2014.187 · DOI
  6. Chang, 2014, American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome, Gastroenterology, 147, 1149, 10.1053/j.gastro.2014.09.002 · DOI
  7. Bressler, 2015, Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: The Toronto consensus, Gastroenterology, 148, 1035, 10.1053/j.gastro.2015.03.001 · DOI · Paper page
  8. Enns, 2017, Clinical practice guidelines for the use of video capsule endoscopy, Gastroenterology, 152, 497, 10.1053/j.gastro.2016.12.032 · DOI
  9. Nguyen, 2016, The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy, Gastroenterology, 150, 734, 10.1053/j.gastro.2015.12.003 · DOI · Paper page
  10. Fallone, 2016, The Toronto consensus for the treatment of helicobacter pylori infection in adults, Gastroenterology, 151, 51, 10.1053/j.gastro.2016.04.006 · DOI
  11. Nguyen, 2014, Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: CANADIAN Association of Gastroenterology, Gastroenterology, 146, 835, 10.1053/j.gastro.2014.01.042 · DOI
  12. Liu, 2018, Clinical practice guidelines for the assessment of uninvestigated esophageal dysphagia, J Can Assoc Gastroenterol, 1, 5, 10.1093/jcag/gwx008 · DOI
  13. Guyatt, 2008, Going from evidence to recommendations, BMJ, 336, 1049, 10.1136/bmj.39493.646875.AE · DOI · Paper page
  14. Ford, 2009, Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: Systematic review and meta-analysis, Arch Intern Med, 169, 651, 10.1001/archinternmed.2009.22 · DOI
  15. Zipser, 2003, Presentations of adult celiac disease in a nationwide patient support group, Dig Dis Sci, 48, 761, 10.1023/A:1022897028030 · DOI
  16. Menees, 2015, A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS, Am J Gastroenterol, 110, 444, 10.1038/ajg.2015.6 · DOI · Paper page
  17. Sood, 2016, Enhancing diagnostic performance of symptom-based criteria for irritable bowel syndrome by additional history and limited diagnostic evaluation, Am J Gastroenterol, 111, 1446, 10.1038/ajg.2016.308 · DOI
  18. Ford, 2013, Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care, Gastroenterology, 145, 1262, 10.1053/j.gastro.2013.08.048 · DOI
  19. Hilmi, 2013, Low prevalence of ‘classical’ microscopic colitis but evidence of microscopic inflammation in Asian irritable bowel syndrome patients with diarrhoea, BMC Gastroenterol, 13, 80, 10.1186/1471-230X-13-80 · DOI
  20. Ishihara, 2012, Prevalence of organic colonic lesions in patients meeting Rome III criteria for diagnosis of IBS: A prospective multi-center study utilizing colonoscopy, J Gastroenterol, 47, 1084, 10.1007/s00535-012-0573-4 · DOI
  21. Gu, 2011, Organic colonic lesions in 3,332 patients with suspected irritable bowel syndrome and lacking warning signs, a retrospective case–control study, Int J Colorectal Dis, 26, 935, 10.1007/s00384-011-1163-2 · DOI
  22. Akhtar, 2006, Organic colonic lesions in patients with irritable bowel syndrome (IBS), Med Sci Monit, 12, CR363
  23. Hamm, 1999, Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria, Am J Gastroenterol, 94, 1279, 10.1111/j.1572-0241.1999.01077.x · DOI
  24. El-Salhy, 2011, The prevalence of inflammatory bowel diseases, microscopic colitis, and colorectal cancer in patients with irritable bowel syndrome, Gastroenterol Insights, 3, 3, 10.4081/gi.2011.e3 · DOI
  25. Şimşek, 2015, Two gastrointestinal conditions with similar symptoms and endoscopic appearance: Irritable bowel syndrome and microscopic colitis, Turk J Med Sci, 45, 393, 10.3906/sag-1401-88 · DOI
  26. Ozdil, 2011, The frequency of microscopic and focal active colitis in patients with irritable bowel syndrome, BMC Gastroenterol, 11, 96, 10.1186/1471-230X-11-96 · DOI
  27. Carmona-Sánchez, 2011, [Prevalence of microscopic colitis in patients with irritable bowel syndrome with diarrhea predominance], Rev Gastroenterol Mex, 76, 39
  28. Tunçer, 2003, Prevalence of microscopic colitis in patients with symptoms suggesting irritable bowel syndrome, Acta Gastroenterol Belg, 66, 133
  29. De Silva, 2012, Subclinical mucosal inflammation in diarrhea-predominant irritable bowel syndrome (IBS) in a tropical setting, Scand J Gastroenterol, 47, 619, 10.3109/00365521.2012.666672 · DOI
  30. Pan, 2016, Trends in irritable bowel syndrome incidence among Taiwanese adults during 2003–2013: A population-based study of sex and age differences, PLoS One, 11, e0166922, 10.1371/journal.pone.0166922 · DOI
  31. Ford, 2008, Diagnostic utility of alarm features for colorectal cancer: Systematic review and meta-analysis, Gut, 57, 1545, 10.1136/gut.2008.159723 · DOI · Paper page
  32. Šimundić, 2009, Measures of diagnostic accuracy: Basic definitions, ejifcc, 19, 203
  33. Fuchs, 1994, a prospective study of family history and the risk of colorectal cancer, N Engl J Med, 331, 1669, 10.1056/NEJM199412223312501 · DOI · Paper page
  34. Bacchus, 2016, Recommendations on screening for colorectal cancer in primary care, CMAJ, 188, 340, 10.1503/cmaj.151125 · DOI
  35. Cash, 2002, The utility of diagnostic tests in irritable bowel syndrome patients: A systematic review, Am J Gastroenterol, 97, 2812, 10.1111/j.1572-0241.2002.07027.x · DOI
  36. Canavan, 2014, The incidence of other gastroenterological disease following diagnosis of irritable bowel syndrome in the UK: A cohort study, PLoS One, 9, e106478, 10.1371/journal.pone.0106478 · DOI
  37. Thomson, 2003, The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: The Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study, Aliment Pharmacol Ther, 17, 1481, 10.1046/j.1365-2036.2003.01646.x · DOI · Paper page
  38. Patel, 2015, Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: Cross-sectional survey, Scand J Gastroenterol, 50, 816, 10.3109/00365521.2015.1007079 · DOI
  39. Lin, 2016, Screening for colorectal cancer: Updated evidence report and systematic review for the us preventive services task Force, JAMA, 315, 2576, 10.1001/jama.2016.3332 · DOI
  40. Brenner, 2014, Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: Systematic review and meta-analysis of randomised controlled trials and observational studies, BMJ, 348, g2467, 10.1136/bmj.g2467 · DOI
  41. Atkinson, 2004, Food elimination based on IgG antibodies in irritable bowel syndrome: A randomised controlled trial, Gut, 53, 1459, 10.1136/gut.2003.037697 · DOI · Paper page
  42. Park, 2006, Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? A systematic review, Neurogastroenterol Motil, 18, 595, 10.1111/j.1365-2982.2005.00745.x · DOI
  43. Eswaran, 2011, Food: The forgotten factor in the irritable bowel syndrome, Gastroenterol Clin North Am, 40, 141, 10.1016/j.gtc.2010.12.012 · DOI
  44. Bischoff, 1996, Prevalence of adverse reactions to food in patients with gastrointestinal disease, Allergy, 51, 811, 10.1111/j.1398-9995.1996.tb04471.x · DOI
  45. Dainese, 1999, Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients, Am J Gastroenterol, 94, 1892, 10.1111/j.1572-0241.1999.01226.x · DOI
  46. Capili, 2016, Addressing the role of food in irritable bowel syndrome symptom management, J Nurse Pract, 12, 324, 10.1016/j.nurpra.2015.12.007 · DOI · Paper page
  47. Tolliver, 1996, Does lactose maldigestion really play a role in the irritable bowel, J Clin Gastroenterol, 23, 15, 10.1097/00004836-199607000-00005 · DOI
  48. Vernia, 1995, Lactose malabsorption and irritable bowel syndrome. Effect of a long-term lactose-free diet, Ital J Gastroenterol, 27, 117
  49. Parker, 2001, Irritable bowel syndrome: Is the search for lactose intolerance justified, Eur J Gastroenterol Hepatol, 13, 219, 10.1097/00042737-200103000-00001 · DOI
  50. Bozzani, 1986, Lactose malabsorption and intolerance in Italians. Clinical implications, Dig Dis Sci, 31, 1313, 10.1007/BF01299809 · DOI
  51. Böhmer, 1996, The clinical relevance of lactose malabsorption in irritable bowel syndrome, Eur J Gastroenterol Hepatol, 8, 1013, 10.1097/00042737-199610000-00015 · DOI
  52. Böhmer, 2001, The effect of a lactose-restricted diet in patients with a positive lactose tolerance test, earlier diagnosed as irritable bowel syndrome: A 5-year follow-up study, Eur J Gastroenterol Hepatol, 13, 941, 10.1097/00042737-200108000-00011 · DOI
  53. Ghoshal, 2010, Frequency of small intestinal bacterial overgrowth in patients with irritable bowel syndrome and chronic non-specific diarrhea, J Neurogastroenterol Motil, 16, 40, 10.5056/jnm.2010.16.1.40 · DOI
  54. Sosa, 2016, Glucose breath test in patients with overlapping FD and IBS. Is there any difference compared to patients with only FD or only IBS? [Abstract Tu1738], Gastroenterology, 150, S929, 10.1016/S0016-5085(16)33149-3 · DOI
  55. Ghoshal, 2017, Small intestinal bacterial overgrowth and irritable bowel syndrome: A bridge between functional organic dichotomy, Gut Liver, 11, 196, 10.5009/gnl16126 · DOI
  56. Eswaran, 2016, A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D, Am J Gastroenterol, 111, 1824, 10.1038/ajg.2016.434 · DOI
  57. Böhn, 2015, Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: A randomized controlled trial, Gastroenterology, 149, 1399, 10.1053/j.gastro.2015.07.054 · DOI · Paper page
  58. McIntosh, 2017, FODMAPs alter symptoms and the metabolome of patients with IBS: A randomised controlled trial, Gut, 66, 1241, 10.1136/gutjnl-2015-311339 · DOI · Paper page
  59. Staudacher, 2012, Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome, J Nutr, 142, 1510, 10.3945/jn.112.159285 · DOI · Paper page
  60. Staudacher, 2016, The low FODMAP diet reduces symptoms in irritable bowel syndrome compared with placebo diet and the microbiota alterations may be prevented by probiotic co-administration: a 2X2 factorial randomized controlled trial [Abstract 1133], Gastroenterology, 150, 10.1016/S0016-5085(16)30842-3 · DOI
  61. Staudacher, 2017, Nutritional, microbiological and psychosocial implications of the low FODMAP diet, J Gastroenterol Hepatol, 32, 16, 10.1111/jgh.13688 · DOI
  62. Murray, 2014, Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI, Am J Gastroenterol, 109, 110, 10.1038/ajg.2013.386 · DOI · Paper page
  63. Barrett, 2010, Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon, Aliment Pharmacol Ther, 31, 874, 10.1111/j.1365-2036.2010.04237.x · DOI · Paper page
  64. Hayes, 2014, A dietary survey of patients with irritable bowel syndrome, J Hum Nutr Diet, 27, 36, 10.1111/jhn.12114 · DOI
  65. Nanayakkara, 2016, Efficacy of the low FODMAP diet for treating irritable bowel syndrome: The evidence to date, Clin Exp Gastroenterol, 9, 131
  66. Biesiekierski, 2011, Gluten causes gastrointestinal symptoms in subjects without celiac disease: A double-blind randomized placebo-controlled trial, Am J Gastroenterol, 106, 508, 10.1038/ajg.2010.487 · DOI · Paper page
  67. Shahbazkhani, 2015, Non-celiac gluten sensitivity has narrowed the spectrum of irritable bowel syndrome: A double-blind randomized placebo-controlled trial, Nutrients, 7, 4542, 10.3390/nu7064542 · DOI
  68. Biesiekierski, 2013, No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates, Gastroenterology, 145, 320, 10.1053/j.gastro.2013.04.051 · DOI · Paper page
  69. Gaesser, 2012, Gluten-free diet: Imprudent dietary advice for the general population, J Acad Nutr Diet, 112, 1330, 10.1016/j.jand.2012.06.009 · DOI
  70. Wild, 2010, Evidence of high sugar intake, and low fibre and mineral intake, in the gluten-free diet, Aliment Pharmacol Ther, 32, 573, 10.1111/j.1365-2036.2010.04386.x · DOI · Paper page
  71. Lee, 2007, Economic burden of a gluten-free diet, J Hum Nutr Diet, 20, 423, 10.1111/j.1365-277X.2007.00763.x · DOI · Paper page
  72. Moayyedi, 2014, The effect of fiber supplementation on irritable bowel syndrome: A systematic review and meta-analysis, Am J Gastroenterol, 109, 1367, 10.1038/ajg.2014.195 · DOI
  73. Kamiya, 2014, Therapeutic effects of biobran, modified arabinoxylan rice bran, in improving symptoms of diarrhea predominant or mixed type irritable bowel syndrome: A pilot, randomized controlled study, Evid Based Complement Alternat Med, 2014, 828137, 10.1155/2014/828137 · DOI
  74. Singh, 2007, Psyllium as therapeutic and drug delivery agent, Int J Pharm, 334, 1, 10.1016/j.ijpharm.2007.01.028 · DOI · Paper page
  75. Li, 2015, A systematic review of integrated traditional Chinese and Western medicine for managing irritable bowel syndrome, Am J Chin Med, 43, 385, 10.1142/S0192415X15500251 · DOI
  76. Rahimi, 2012, Herbal medicines for the management of irritable bowel syndrome: A comprehensive review, World J Gastroenterol, 18, 589, 10.3748/wjg.v18.i7.589 · DOI
  77. Shi, 2008, Effectiveness and safety of herbal medicines in the treatment of irritable bowel syndrome: A systematic review, World J Gastroenterol, 14, 454, 10.3748/wjg.14.454 · DOI
  78. Lim, 2006, Acupuncture for treatment of irritable bowel syndrome, Cochrane Database Syst Rev, CD005111
  79. Manheimer, 2012, Acupuncture for treatment of irritable bowel syndrome, Cochrane Database Syst Rev, CD005111
  80. Lowe, 2017, Sham acupuncture is as efficacious as true acupuncture for the treatment of IBS: A randomized placebo controlled trial, Neurogastroenterol Motil, 29, e13040, 10.1111/nmo.13040 · DOI
  81. White, 2001, Adverse events following acupuncture: Prospective survey of 32 000 consultations with doctors and physiotherapists, BMJ, 323, 485, 10.1136/bmj.323.7311.485 · DOI
  82. Wu, 2015, Systematic review of adverse effects: A further step towards modernization of acupuncture in China, Evid Based Complement Alternat Med, 2015, 432467, 10.1155/2015/432467 · DOI
  83. Park, 2016, Adverse events associated with acupuncture: A clinicopathologic review, Int J Dermatol, 55, 757, 10.1111/ijd.12914 · DOI
  84. Ford, 2008, Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: Systematic review and meta-analysis, BMJ, 337, a2313, 10.1136/bmj.a2313 · DOI · Paper page
  85. Merat, 2010, The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome, Dig Dis Sci, 55, 1385, 10.1007/s10620-009-0854-9 · DOI · Paper page
  86. Cash, 2016, A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms, Dig Dis Sci, 61, 560, 10.1007/s10620-015-3858-7 · DOI
  87. Mosaffa-Jahromi, 2016, Efficacy and safety of enteric coated capsules of anise oil to treat irritable bowel syndrome, J Ethnopharmacol, 194, 937, 10.1016/j.jep.2016.10.083 · DOI
  88. Khanna, 2014, Peppermint oil for the treatment of irritable bowel syndrome: A systematic review and meta-analysis, J Clin Gastroenterol, 48, 505, 10.1097/MCG.0b013e3182a88357 · DOI
  89. Kabir, 2011, Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome, Mymensingh Med J, 20, 397
  90. Ko, 2013, Effect of Korean herbal medicine combined with a probiotic mixture on diarrhea-dominant irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial, Evid Based Complement Alternat Med, 2013, 824605, 10.1155/2013/824605 · DOI
  91. Stevenson, 2014, Randomized clinical trial: Effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome, Nutrition, 30, 1151, 10.1016/j.nut.2014.02.010 · DOI
  92. Jafari, 2014, Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating, Arch Iran Med, 17, 466
  93. Ludidi, 2014, Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients, Neurogastroenterol Motil, 26, 705, 10.1111/nmo.12320 · DOI
  94. Yoon, 2014, Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial, J Gastroenterol Hepatol, 29, 52, 10.1111/jgh.12322 · DOI
  95. Lorenzo-Zúñiga, 2014, I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life, World J Gastroenterol, 20, 8709, 10.3748/wjg.v20.i26.8709 · DOI
  96. Pineton de Chambrun, 2015, A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome, Dig Liver Dis, 47, 119, 10.1016/j.dld.2014.11.007 · DOI
  97. Wong, 2015, Melatonin regulation as a possible mechanism for probiotic (VSL#3) in irritable bowel syndrome: A randomized double-blinded placebo study, Dig Dis Sci, 60, 186, 10.1007/s10620-014-3299-8 · DOI
  98. Yoon, 2015, Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial, J Clin Biochem Nutr, 57, 129, 10.3164/jcbn.15-14 · DOI
  99. Thijssen, 2016, Efficacy of Lactobacillus casei Shirota for patients with irritable bowel syndrome, Eur J Gastroenterol Hepatol, 28, 8, 10.1097/MEG.0000000000000484 · DOI
  100. Hod, 2017, A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS, Neurogastroenterol Motil, 29, e13037, 10.1111/nmo.13037 · DOI
  101. Mercer, 2012, How patients view probiotics: Findings from a multicenter study of patients with inflammatory bowel disease and irritable bowel syndrome, J Clin Gastroenterol, 46, 138, 10.1097/MCG.0b013e318225f545 · DOI
  102. Fernandez, 1998, Stress and contingency management in the treatment of irritable bowel syndrome, Stress Med, 14, 31, 10.1002/(SICI)1099-1700(199801)14:1<31::AID-SMI754>3.0.CO;2-B · DOI
  103. Boltin, 2015, Gut-directed guided affective imagery as an adjunct to dietary modification in irritable bowel syndrome, J Health Psychol, 20, 712, 10.1177/1359105315573450 · DOI · Paper page
  104. Blanchard, 1992, Two controlled evaluations of multicomponent psychological treatment of irritable bowel syndrome, Behav Res Ther, 30, 175, 10.1016/0005-7967(92)90141-3 · DOI
  105. Guthrie, 1991, A controlled trial of psychological treatment for the irritable bowel syndrome, Gastroenterology, 100, 450, 10.1016/0016-5085(91)90215-7 · DOI
  106. Simrén, 2004, Treatment with hypnotherapy reduces the sensory and motor component of the gastrocolonic response in irritable bowel syndrome, Psychosom Med, 66, 233, 10.1097/01.psy.0000116964.76529.6e · DOI · Paper page
  107. Laird, 2017, Comparative efficacy of psychological therapies for improving mental health and daily functioning in irritable bowel syndrome: A systematic review and meta-analysis, Clin Psychol Rev, 51, 142, 10.1016/j.cpr.2016.11.001 · DOI
  108. Clavé, 2011, Randomised clinical trial: Otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome, Aliment Pharmacol Ther, 34, 432, 10.1111/j.1365-2036.2011.04730.x · DOI
  109. Rai, 2014, Efficacy and safety of drotaverine hydrochloride in irritable bowel syndrome: A randomized double-blind placebo-controlled study, Saudi J Gastroenterol, 20, 378, 10.4103/1319-3767.145331 · DOI
  110. Zheng, 2015, Pinaverium reduces symptoms of irritable bowel syndrome in a multicenter, randomized, Controlled Trial, Clin Gastroenterol Hepatol, 13, 1285, 10.1016/j.cgh.2015.01.015 · DOI
  111. Chey, 2015, Irritable bowel syndrome: A clinical review, JAMA, 313, 949, 10.1001/jama.2015.0954 · DOI · Paper page
  112. Verdu, 2008, Antidepressants for the treatment of chronic pain, Drugs, 68, 2611, 10.2165/0003495-200868180-00007 · DOI
  113. Vahedi, 2008, Clinical trial: The effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther, 27, 678, 10.1111/j.1365-2036.2008.03633.x · DOI
  114. Vahedi, 2005, The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: A double-blind randomized-controlled study, Aliment Pharmacol Ther, 22, 381, 10.1111/j.1365-2036.2005.02566.x · DOI
  115. Warner, 2006, Antidepressant discontinuation syndrome, Am Fam Physician, 74, 449
  116. Dekel, 2013, The use of psychotropic drugs in irritable bowel syndrome, Expert Opin Investig Drugs, 22, 329, 10.1517/13543784.2013.761205 · DOI
  117. Hovdenak, 1987, Loperamide treatment of the irritable bowel syndrome, Scand J Gastroenterol Suppl, 130, 81, 10.3109/00365528709091004 · DOI
  118. Lavö, 1987, Loperamide in treatment of irritable bowel syndrome–a double-blind placebo controlled study, Scand J Gastroenterol Suppl, 130, 77, 10.3109/00365528709091003 · DOI
  119. Cann, 1984, Role of loperamide and placebo in management of irritable bowel syndrome (IBS), Dig Dis Sci, 29, 239, 10.1007/BF01296258 · DOI
  120. Efskind, 1996, A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome, Scand J Gastroenterol, 31, 463, 10.3109/00365529609006766 · DOI
  121. Baker, 2007, Loperamide: A pharmacological review, Rev Gastroenterol Disord, 7, S11
  122. Hanauer, 2008, The role of loperamide in gastrointestinal disorders, Rev Gastroenterol Disord, 8, 15
  123. Wedlake, 2009, Systematic review: The prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther, 30, 707, 10.1111/j.1365-2036.2009.04081.x · DOI · Paper page
  124. Lombardo, 2015, A reason why lactose-free diet can be clinically ineffective in lactose intolerance patients [Abstract OP165], United European Gastroenterol J, 3, A54
  125. XIFAXAN® (Rifaximin) Prescribing Information, May 2015
  126. Adachi, 2006, Rifaximin: A novel nonabsorbed rifamycin for gastrointestinal disorders, Clin Infect Dis, 42, 541, 10.1086/499950 · DOI
  127. Di Stefano, 2000, Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms, Aliment Pharmacol Ther, 14, 1001, 10.1046/j.1365-2036.2000.00808.x · DOI
  128. Dove, 2013, Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study, Gastroenterology, 145, 329, 10.1053/j.gastro.2013.04.006 · DOI
  129. Smith, 2016, Eluxadoline in the treatment of irritable bowel syndrome with diarrhea, Clin Med Rev Ther, 8, 15
  130. VIBERZITM (Eluxadoline) Product Monograph, Jan 2017
  131. Hasler, 2003, Systematic review: Abdominal and pelvic surgery in patients with irritable bowel syndrome, Aliment Pharmacol Ther, 17, 997, 10.1046/j.1365-2036.2003.01499.x · DOI
  132. Awad, 2010, A randomized, double-blind, placebo-controlled trial of polyethylene glycol effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation-predominant irritable bowel syndrome, Colorectal Dis, 12, 1131, 10.1111/j.1463-1318.2009.01990.x · DOI · Paper page
  133. Ford, 2009, Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: Systematic review and meta-analysis, Am J Gastroenterol, 104, 1831, 10.1038/ajg.2009.223 · DOI · Paper page
  134. Johanson, 2008, Clinical trial: Phase two study of lubiprostone for irritable bowel syndrome with constipation, Aliment Pharmacol Ther, 27, 685, 10.1111/j.1365-2036.2008.03629.x · DOI
  135. Lacy, 2007, Lubiprostone: A chloride channel activator, J Clin Gastroenterol, 41, 345, 10.1097/01.mcg.0000225665.68920.df · DOI
  136. Ford, 2017, Irritable Bowel Syndrome, N Engl J Med, 376, 2566, 10.1056/NEJMra1607547 · DOI · Paper page
  137. Yang, 2016, Efficacy and safety of linaclotide in patients with IBS-C: Results from a phase 3, randomized, double-blind, placebo-controlled trial in China and other regions [Abstract Mo1646], Gastroenterology, 150, S741, 10.1016/S0016-5085(16)32517-3 · DOI
  138. Chey, 2012, Linaclotide for irritable bowel syndrome with constipation: A 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety, Am J Gastroenterol, 107, 1702, 10.1038/ajg.2012.254 · DOI · Paper page
  139. Rao, 2012, A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation, Am J Gastroenterol, 107, 1714, 10.1038/ajg.2012.255 · DOI
  140. McCormack, 2014, Linaclotide: A review of its use in the treatment of irritable bowel syndrome with constipation, Drugs, 74, 53, 10.1007/s40265-013-0157-5 · DOI
  141. CONSTELLATM (Linaclotide) Product Monograph, May 2014

Cited by

Metadata

Authors
Moayyedi, P., Andrews, C. N., MacQueen, G., Korownyk, C., Marsiglio, M., Graff, L., Kvern, B., Lazarescu, A., Liu, L., Paterson, W. G., Sidani, S., & Vanner, S.
Affiliations
  • Division of Gastroenterology, McMaster University, Hamilton, Ontario, Canada
  • Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada
  • Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada
  • Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada
  • Unaffliated
  • Department of Clinical Health Psychology, University of Manitoba, Winnipeg, Manitoba, Canada
  • Department of Family Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
  • Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada
  • Division of Gastroenterology, University of Toronto, Toronto, Ontario, Canada
  • Division of Gastroenterology, Queen’s University, Kingston, Ontario, Canada
Venue
Journal of the Canadian Association of Gastroenterology
Publisher
Oxford University Press (OUP)
Published
2019-01-17
Volume
2
Issue
1
Pages
6-29
ISSN
  • 2515-2084
  • 2515-2092
DOI
10.1093/jcag/gwy071
Cited by
150
References
36
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.